Quantcast
Last updated on April 16, 2014 at 12:50 EDT

Latest metastatic melanoma Stories

2009-02-10 08:58:46

Scientists have long wondered how melanoma cells travel from primary tumors on the surface of the skin to the brain, liver and lungs, where they become more aggressive, resistant to therapy, and deadly. Now, scientists from NYU Langone Medical Center have identified the possible culprit"”a short strand of RNA called microRNA (miRNA) that is over-expressed in metastatic melanoma cell lines and tissues.The new findings, published online this week and in the February 10, 2009 print edition...

2008-11-03 06:00:21

BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today preliminary data from an ongoing Phase II trial of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, for the treatment of patients with unresectable Stage III or Stage IV melanoma. Dr. Patrick Hwu, Co-Principal Investigator, and Professor and Chairman of the Department of Melanoma Medical Oncology, at The University of Texas M. D. Anderson Cancer Center, presented the data during an oral...

2008-10-14 09:00:11

Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has achieved operational milestones triggering $25 million in payment from GlaxoSmithKline (GSK) under its collaboration agreement for the development and commercialization of elesclomol. Elesclomol is a novel, oxidative stress inducing, small molecule drug candidate currently...

2008-10-06 12:00:42

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that that the interim safety analysis on the first 20 subjects in its phase 2 clinical trial for the treatment of metastatic melanoma has been completed. PV-10 injection was well tolerated by this group, with an adverse event profile similar to that observed in phase 1. In addition, long-term survival data for subjects participating in the phase 1 trial were...

2008-09-15 12:00:35

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that two-year follow up survival data from its Phase 2b clinical trial in metastatic melanoma were presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. In addition, an integrated safety analysis from Phase 1 and Phase 2 solid tumor trials of elesclomol plus paclitaxel versus paclitaxel alone was presented. Elesclomol is an investigational drug candidate that triggers programmed cell death...

2008-08-22 09:01:11

Synta Pharmaceuticals Corp., (NASDAQ: SNTA) today announced the publication of new findings in the American Association for Cancer Research journal, Molecular Cancer Therapeutics that describe the novel mechanism of action of elesclomol: driving programmed cell death (apoptosis) in cancer cells through the selective induction of oxidative stress. Elesclomol is currently in a global, pivotal Phase 3 clinical trial (SYMMETRY(SM)) in combination with paclitaxel for the treatment of metastatic...

2008-01-07 12:00:48

A patient at The Angeles Clinic and Research Institute is the first to enter a global, pivotal Phase 3 clinical trial for treating advanced melanoma. The experimental drug, Elesclomol, attacks cancer in an entirely new way and has shown promise in treating metastatic melanoma, delaying progression of the disease and possibly prolonging the lives of patients. Elesclomol has a completely new and distinct mechanism of action from other cancer therapies as it induces a potent stress...

2005-11-17 17:26:18

Northwestern University researchers have demonstrated how the microenvironments of two human embryonic stem cell (hESC) lines (federally approved) induced metastatic melanoma cells to revert to a normal, skin cell-like type with the ability to form colonies similar to hESCs. The researchers also showed that these melanoma cells were less invasive following culture on the microenvironments of hESCs. "Our observations highlight the potential utility of isolating the factors within the hESC...